Art. -Nr.: HY-N0837

Veratramine

(Synonyms: NSC17821; NSC23880)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.88%
CAS. Nr.: 60-70-8
Formel: C₂₇H₃₉NO₂
Molecular Weight:409.60

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Veratramine Chemical Structure

CAS. Nr.: 60-70-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) Veratramine

Pharm Biol. 2022 Dec;60(1):2145-2154. [Abstract]

Customer Validation & Images

IHCWBRT-PCRHistological Imaging/Staining

IHC
WB
RT-PCR
Histological Imaging/Staining

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

In Vitro

Veratramine (2.5-80 μM; 24-72 h) inhibits cell proliferation, migration and invasion, induces G0/G1 arrest and autophagic apoptosis, and downregulates proteins related to the PI3K/Akt/mTOR signaling pathway in human hepatoma HepG2 cell experiments^[1].
Veratramine (30-50 μM; 24-48 h) inhibits cell viability, migration and invasion, induces apoptosis, and downregulates p-PI3K, p-Akt, and EMT-related proteins N-cadherin and vimentin in human osteosarcoma 143B and HOS cell experiments^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:

HepG2 liver cancer cells
Concentration:

10, 20, 40 μM
Incubation Time:

48 h
Result:

Flow cytometry revealed a dose-dependent increase in apoptotic cells (Annexin V+), with the highest apoptosis rate (51.86%) at 40 μM.
Cell cycle analysis showed G0/G1 phase arrest, with a significant reduction in S phase cells at 40 μM.

Western Blot Analysis^[1]

Cell Line:

HepG2 liver cancer cells
Concentration:

0, 10, 20, 40 μM
Incubation Time:

48 h
Result:

Downregulated p-PI3K, p-Akt, and p-mTOR, and upregulated autophagy markers Beclin-1 and LC3-II/I.
Pro-apoptotic protein Bax was increased, while anti-apoptotic Bcl-2 was decreased.

Cell Migration Assay ^[2]

Cell Line:

143B and HOS osteosarcoma cells
Concentration:

0, 30, 40, 50 μM
Incubation Time:

24-48 h
Result:

Wound healing and Transwell assays showed reduced migration and invasion at 40 μM and 50 μM.

Western Blot Analysis^[2]

Cell Line:

143B and HOS osteosarcoma cells
Concentration:

0, 30, 40, 50 μM
Incubation Time:

24-48 h
Result:

Western blot revealed decreased N-cadherin, Snail, vimentin, and MMP-2, indicating inhibition of epithelial-mesenchymal transition (EMT).

In Vivo

Veratramine (2 mg/kg; tail vein injection; 3 times a week; 4 weeks) inhibits tumor growth and reduces tumor weight in the subcutaneous transplant model of liver cancer in BALB/c nude mice, without obvious systemic toxicity^[1].
Veratramine (50 μg/kg; tail vein injection; once a day; 4 weeks) increases the mechanical pain threshold in the diabetic peripheral neuropathy model of Sprague-Dawley rats, prolongs the tolerance time to cold and hot stimuli, and reduces the pathological damage of the spinal cord and sciatic nerve^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c Nude Mouse Hepatocellular Carcinoma Model (female, 16-18 g, 4-6 weeks old): subcutaneous hepatocellular carcinoma xenografts (HepG2 cells)^[1]
Dosage:

2 mg/kg
Administration:

Tail vein injection, 3 times a week for 4 weeks
Result:

Significantly decreased the tumor volume was smaller compared to the control group. Reduced the average tumor weight.
There were no significant differences in body weight, food intake, or water intake between the two groups.
Led to a decrease in the number of proliferating cells and an increase in apoptotic cells in the tumor tissue in Histopathological examination.

Animal Model:

Sprague-Dawley Rat Diabetic Peripheral Neuropathy Model (male, 260-300 g, 8 weeks old): Streptozotocin-induced diabetic peripheral neuropathy^[3]
Dosage:

50 µg/kg
Administration:

Tail vein injection, once a day for 4 weeks
Result:

Significantly increased he mechanical pain threshold and cold/hot stimulus tolerance time compared to the diabetic control group.
Resulted the spinal cord and sciatic nerve less damage in Histological examination.
Downregulated the expression of p-mTOR and p-4E-BP1 in the spinal cord and sciatic nerve tissues.

Chemical Information

CAS. Nr. 60-70-8
Appearance Solid
Molecular Weight 409.60
Formel C₂₇H₃₉NO₂
Color White to off-white
SMILES

O[C@H]1[C@H]([C@H](C2=C(C)C3=C(C=C2)[C@]4([H])CC=C(C[C@@H](O)CC5)[C@@]5(C)[C@@]4([H])C3)C)NC[C@@H](C)C1
Synonyms

NSC17821; NSC23880
Structure Classification
- Alkaloids
- Piperidine Alkaloids
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All IHCWBRT-PCRHistological Imaging/Staining

Sort by:

Journal Impact Factor

Pharm Biol

Veratramine ameliorates pain symptoms in rats with diabetic peripheral neuropathy by inhibiting activation of the SIGMAR1-NMDAR pathway. [Abstract]

2022 Dec;60(1):2145-2154. PMID: 36373991

Veratramine purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):2145-2154. [Abstract]

Immunohistochemistry (IHC) was used to stain and localise SIGMAR1 protein in rat spinal cord tissue treated with Veratramine (50 μg/kg, tail vein).

Veratramine purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):2145-2154. [Abstract]

WB was used to detect the protein expression level of SIGMAR1 treated with Veratramine (50 μg/kg, tail vein).

Veratramine purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):2145-2154. [Abstract]

The spinal cord tissues of rats in each group were examined for SIGMAR1 gene expression leves by qPCR treated with Veratramine (50 μg/kg, tail vein).

Veratramine purchased from MedChemExpress. Usage Cited in: Pharm Biol. 2022 Dec;60(1):2145-2154. [Abstract]

H&E photomicrographs of spinal cord tissue treated with Veratramine (50 μg/kg, tail vein).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (244.14 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4414 mL

12.2070 mL

24.4141 mL

5 mM

0.4883 mL

2.4414 mL

4.8828 mL

10 mM

0.2441 mL

1.2207 mL

2.4414 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yin L, et al. Veratramine suppresses human HepG2 liver cancer cell growth in vitro and in vivo by inducing autophagic cell death. Oncol Rep. 2020 Aug;44(2):477-486. [Content Brief]

[2]. Xie Z, et al. Veratramine influences the proliferation of human osteosarcoma cells through modulation of the PI3K/AKT signaling cascade. Genes & Diseases, 2025: 101630.

[3]. Zhang Y,et al. Veratramine ameliorates pain symptoms in rats with diabetic peripheral neuropathy by inhibiting activation of the SIGMAR1-NMDAR pathway. Pharm Biol. 2022 Dec;60(1):2145-2154. [Content Brief]

[4]. Wang L, et al. Hypotensive effect and toxicology of total alkaloids and veratramine from roots and rhizomes of Veratrum nigrum L. in spontaneously hypertensive rats. Pharmazie. 2008 Aug;63(8):606-10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4414 mL	12.2070 mL	24.4141 mL	61.0352 mL
	5 mM	0.4883 mL	2.4414 mL	4.8828 mL	12.2070 mL
	10 mM	0.2441 mL	1.2207 mL	2.4414 mL	6.1035 mL
	15 mM	0.1628 mL	0.8138 mL	1.6276 mL	4.0690 mL
	20 mM	0.1221 mL	0.6104 mL	1.2207 mL	3.0518 mL
	25 mM	0.0977 mL	0.4883 mL	0.9766 mL	2.4414 mL
	30 mM	0.0814 mL	0.4069 mL	0.8138 mL	2.0345 mL
	40 mM	0.0610 mL	0.3052 mL	0.6104 mL	1.5259 mL
	50 mM	0.0488 mL	0.2441 mL	0.4883 mL	1.2207 mL
	60 mM	0.0407 mL	0.2035 mL	0.4069 mL	1.0173 mL
	80 mM	0.0305 mL	0.1526 mL	0.3052 mL	0.7629 mL
	100 mM	0.0244 mL	0.1221 mL	0.2441 mL	0.6104 mL

Keywords

Veratramine

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Veratramine

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Veratramine

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen

Biologische Aktivität